Atezolizumab

🧮 Dose calculator

Lung cancer (small-cell and non-small-cell) · Regimen source: FDA Tecentriq · 2.2, Table 1

• • Only under an oncologist; continue until progression or unacceptable toxicity. Dose adjustments for toxicity and interactions per label. FDA Tecentriq · 2.2
• • First infusion over 60 min, then 30 min if tolerated. Adjuvant NSCLC: up to 1 year. FDA Tecentriq · 2.2

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyDangerous / avoid

  Label: can cause fetal harm. Dangerous in pregnancy. FDA Tecentriq · 8.1

  “Risk Summary Based on its mechanism of action [see Clinical Pharmacology (12.1) ] , TECENTRIQ can cause fetal harm when administered to a pregnant woman.”

• 🤱 BreastfeedingDangerous / avoid

  Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Tecentriq · 8.2

  “Because of the potential for serious adverse reactions in breastfed infants from TECENTRIQ, advise women not to breastfeed during treatment and for at least 5 months after the last dose.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Tecentriq · 8.4

  “Alveolar Soft Part Sarcoma The safety and effectiveness of TECENTRIQ for unresectable or metastatic ASPS have been established in pediatric patients aged 2 years and older.”

• 👴 Older adultsNo specific problem stated

  Label: no specific difference or dose adjustment stated for older adults. FDA Tecentriq · 8.5

  “No overall differences in safety or effectiveness were observed between patients aged 65 years or older and younger patients.”

• ⚥ Females & males of reproductive potentialUse with caution

  Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Tecentriq · 8.3

  “Contraception Females Based on its mechanism of action, TECENTRIQ can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1) ] .”